121 related articles for article (PubMed ID: 31898184)
1. NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma.
Molina AM; van der Mijn JC; Christos P; Wright J; Thomas C; Dutcher JP; Nanus DM; Tagawa ST; Gudas LJ
Invest New Drugs; 2020 Oct; 38(5):1383-1389. PubMed ID: 31898184
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
Pinto N; DuBois SG; Marachelian A; Diede SJ; Taraseviciute A; Glade Bender JL; Tsao-Wei D; Groshen SG; Reid JM; Haas-Kogan DA; Reynolds CP; Kang MH; Irwin MS; Macy ME; Villablanca JG; Matthay KK; Park JR
Pediatr Blood Cancer; 2018 Jul; 65(7):e27023. PubMed ID: 29603591
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
Dasari A; Gore L; Messersmith WA; Diab S; Jimeno A; Weekes CD; Lewis KD; Drabkin HA; Flaig TW; Camidge DR
Invest New Drugs; 2013 Feb; 31(1):115-25. PubMed ID: 22415798
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
Zibelman M; Wong YN; Devarajan K; Malizzia L; Corrigan A; Olszanski AJ; Denlinger CS; Roethke SK; Tetzlaff CH; Plimack ER
Invest New Drugs; 2015 Oct; 33(5):1040-7. PubMed ID: 26091915
[TBL] [Abstract][Full Text] [Related]
5. Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials.
Bacoyiannis C; Dimopoulos MA; Kalofonos HP; Nicolaides C; Aravantinos G; Bafaloukos D; Samelis G; Onyenadum A; Kiamouris Ch; Skarlos D; Pavlidis N; Triantafillidis A; Kosmidis P;
Oncology; 2002; 63(2):130-8. PubMed ID: 12239447
[TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma.
Vaishampayan U; Flaherty L; Du W; Hussain M
Cancer; 2001 Aug; 92(3):519-23. PubMed ID: 11505395
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.
Wood A; George S; Adra N; Chintala S; Damayanti N; Pili R
Invest New Drugs; 2020 Aug; 38(4):1108-1116. PubMed ID: 31654285
[TBL] [Abstract][Full Text] [Related]
8. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.
Park H; Garrido-Laguna I; Naing A; Fu S; Falchook GS; Piha-Paul SA; Wheler JJ; Hong DS; Tsimberidou AM; Subbiah V; Zinner RG; Kaseb AO; Patel S; Fanale MA; Velez-Bravo VM; Meric-Bernstam F; Kurzrock R; Janku F
Oncotarget; 2016 Oct; 7(41):67521-67531. PubMed ID: 27589687
[TBL] [Abstract][Full Text] [Related]
9. Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.
Pili R; Liu G; Chintala S; Verheul H; Rehman S; Attwood K; Lodge MA; Wahl R; Martin JI; Miles KM; Paesante S; Adelaiye R; Godoy A; King S; Zwiebel J; Carducci MA
Br J Cancer; 2017 Mar; 116(7):874-883. PubMed ID: 28222071
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
Quinn DI; Tsao-Wei DD; Twardowski P; Aparicio AM; Frankel P; Chatta G; Wright JJ; Groshen SG; Khoo S; Lenz HJ; Lara PN; Gandara DR; Newman E
Invest New Drugs; 2021 Jun; 39(3):812-820. PubMed ID: 33409898
[TBL] [Abstract][Full Text] [Related]
11. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
Mahalingam D; Mita M; Sarantopoulos J; Wood L; Amaravadi RK; Davis LE; Mita AC; Curiel TJ; Espitia CM; Nawrocki ST; Giles FJ; Carew JS
Autophagy; 2014 Aug; 10(8):1403-14. PubMed ID: 24991835
[TBL] [Abstract][Full Text] [Related]
12. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
Fouladi M; Park JR; Stewart CF; Gilbertson RJ; Schaiquevich P; Sun J; Reid JM; Ames MM; Speights R; Ingle AM; Zwiebel J; Blaney SM; Adamson PC
J Clin Oncol; 2010 Aug; 28(22):3623-9. PubMed ID: 20606092
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma.
Stadler WM; Kuzel T; Dumas M; Vogelzang NJ
J Clin Oncol; 1998 May; 16(5):1820-5. PubMed ID: 9586896
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
Reguart N; Rosell R; Cardenal F; Cardona AF; Isla D; Palmero R; Moran T; Rolfo C; Pallarès MC; Insa A; Carcereny E; Majem M; De Castro J; Queralt C; Molina MA; Taron M
Lung Cancer; 2014 May; 84(2):161-7. PubMed ID: 24636848
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.
Négrier S; Pérol D; Bahleda R; Hollebecque A; Chatelut E; Boyle H; Cassier P; Metzger S; Blanc E; Soria JC; Escudier B
BMC Cancer; 2017 Aug; 17(1):547. PubMed ID: 28810837
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial.
Luu T; Frankel P; Beumer JH; Lim D; Cristea M; Appleman LJ; Lenz HJ; Gandara DR; Kiesel BF; Piekarz RL; Newman EM
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1201-1208. PubMed ID: 31522242
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
Aggarwal R; Thomas S; Pawlowska N; Bartelink I; Grabowsky J; Jahan T; Cripps A; Harb A; Leng J; Reinert A; Mastroserio I; Truong TG; Ryan CJ; Munster PN
J Clin Oncol; 2017 Apr; 35(11):1231-1239. PubMed ID: 28221861
[TBL] [Abstract][Full Text] [Related]
18. A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.
Powles T; Foreshew SJ; Shamash J; Sarwar N; Crabb S; Sahdev A; Nixon J; Lim L; Pungaliya A; Foreshaw A; Davies R; Greenwood M; Wilson P; Pacey S; Galazi M; Jones R; Chowdhury S
Eur J Cancer; 2014 Aug; 50(12):2057-64. PubMed ID: 24908540
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Hudes GR; Ginsberg MS; Baum MS; Harmon CS; Kim ST; Chen I; Redman BG
Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
Schelman WR; Traynor AM; Holen KD; Kolesar JM; Attia S; Hoang T; Eickhoff J; Jiang Z; Alberti D; Marnocha R; Reid JM; Ames MM; McGovern RM; Espinoza-Delgado I; Wright JJ; Wilding G; Bailey HH
Invest New Drugs; 2013 Dec; 31(6):1539-46. PubMed ID: 24114121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]